PMGC Holdings Inc. reports news across a holding-company portfolio that includes precision manufacturing, aerospace and defense supply-chain operations, industrial packaging, defense technology, and bioscience subsidiaries. Recurring company updates cover subsidiary long-term supply agreements, ITAR and aerospace quality standards, customer relationships, manufacturing capacity, and capital actions tied to acquisition-led platform development.
PMGC news also covers NorthStrive Biosciences patent filings and manufacturing work for engineered probiotic assets such as EL-22 and EL-32, as well as Pacific Sun Packaging activity in electronics and IT hardware packaging markets. Defense technology announcements describe subsidiary initiatives involving autonomous systems, counter-drone applications, and GPS-denied navigation environments.
NorthStrive Defense Tech (NASDAQ: ELAB) acquired an exclusive option to license U.S. Patent No. 12,291,334 for a multi-domain drone system that transports cable-suspended payloads through water while flying above the surface. Key capabilities include buoyancy-assisted payload efficiency, trajectory optimization, and operation in coastal, riverine, and flood-prone areas.
The Option Agreement allows development and financing during the Option Period; exercise would trigger negotiation of a definitive license to commercialize the technology. No guarantee of a final license or commercialization is provided.
PMGC Holdings (NASDAQ: ELAB) announced the formation of a wholly owned subsidiary, NorthStrive Defense Tech LLC, to target defense technology with emphasis on drones, autonomous systems, and unmanned defense solutions.
The subsidiary will pursue acquisitions, licensing, and partnerships and plans to leverage PMGC's existing operating subsidiaries, AGA Precision Systems and Silicon Valley Machining, to accelerate commercialization. The company warned there is no assurance these efforts will generate revenue or operational success and said a follow-up announcement is planned.
AGA Precision Systems (NASDAQ: ELAB) executed a Long-Term Agreement (LTA) with Turbo-Jet Products on March 31, 2026 to supply mission-critical aerospace and defense components.
The LTA establishes a five-year initial term with annual renewal provisions and governs future purchase orders, supporting regulated U.S. government and defense-related programs. AGA cites its AS9100 certification and ITAR compliance as enablers for quality, traceability, and regulatory adherence.
PMGC Holdings (NASDAQ: ELAB) filed its Form 10-K for fiscal year ended December 31, 2025, reporting a year of capital deployment and asset growth. Total assets rose 43% to approximately $12.87M and shareholders' equity increased to about $7.84M.
The company completed three acquisitions in 2025 (Pacific Sun Packaging on July 7, AGA Precision Systems on July 18, and Indarg Engineering on Oct 26) to expand precision manufacturing and specialty IT packaging operations, and advanced biopharma subsidiary Northstrive with clinical and preclinical programs targeting muscle preservation alongside GLP-1 therapies.
NorthStrive Biosciences (NASDAQ: ELAB) announced a third amendment to its License Agreement with MOA Life Plus (KOSDAQ: 142760) covering dual myostatin assets EL-32 and EL-22.
The Amendment updates the timing and key development milestones for human clinical programs, aligning schedules with both parties' R&D and regulatory expectations and reinforcing disciplined development planning for the human health portfolio.
PMGC (NASDAQ: PMGC) announced that its wholly owned subsidiary SVM Machining completed ITAR registration on March 24, 2026 and is in compliance with U.S. export‑control rules.
The company said the registration enables SVM to pursue defense and aerospace programs, increases eligibility as a qualified supplier to Tier 1 defense contractors and supports PMGC's strategy to expand into high‑value, defense‑related manufacturing.
PMGC Holdings (Nasdaq: ELAB) subsidiary NorthStrive Biosciences initiated a preclinical study of EL-32 to evaluate preservation of lean muscle while promoting fat loss, alone and combined with GLP-1 therapy semaglutide. The DIO mouse study will assess body weight, fat mass, lean mass, glycemic markers, and composition, with dosing, analysis, and CRO reporting planned over the coming months to inform potential follow-on studies.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-6 reverse stock split of its common stock, effective 12:00 AM ET on March 10, 2026. Each six shares will consolidate into one, fractional holders will receive whole shares, and the CUSIP will change to 73017P508.
The company expects ~3,248,764 shares outstanding before the Split and ~541,461 shares outstanding immediately after, with outstanding awards, options and warrants adjusted proportionally.
NorthStrive Biosciences (Nasdaq: ELAB) filed ten U.S. patent applications on Feb. 19, 2026, extending its EL-22 and EL-32 technologies into animal health and agricultural markets.
The filings cover muscle growth and yield in livestock and poultry, aquaculture growth and emissions reduction, and list ten U.S. application numbers for EL-22 and EL-32.
NorthStrive Biosciences (NASDAQ: ELAB) executed a definitive, exclusive license agreement with Modulant Biosciences for its EL-22 and EL-32 myostatin-engineered probiotic programs for non-human animal health (worldwide excluding the Republic of Korea).
The License grants Modulant exclusive, royalty-bearing, sublicensable rights to develop, manufacture, and commercialize products from issued patents, pending applications, and know-how; Modulant assumes development, regulatory, manufacturing, and commercialization responsibilities while the agreement excludes any human pharmaceutical applications.